Health Pirates
Outstanding clinical teacher
July 2001
Dr. Thomas J. Walsh, senior investigator, pediatric oncology
branch, NCI, was awarded this year’s Clinical Teacher Award.
The award recognizes excellence in clinical training involving
the direct care of patients by any senior clinical investigator
at NIH. Clinical associates nominate individuals who, in their
judgment, have contributed significantly to the professional
development of clinical trainees. A panel of NIH fellows makes
the final selection. Pictured (l to r), Dr. Thomas J. Walsh, Dr.
James Gully, Dr. John Gallin and Rob McClure.
more recently……
NIH Audit Criticizes Scientist’s Dealings
A researcher received more than $100,000 from drug firms.
The agency calls it ’serious misconduct’ but has issued no penalty.
By David Willman, Times Staff Writer
September 10, 2006
WASHINGTON — A senior researcher at the National Institutes
of Health engaged in “serious misconduct” by entering into dozens
of unauthorized private arrangements with drug companies and
failing to report annually the outside income, totaling more than
$100,000, a confidential internal review by the agency has found.
Transparency needed in drug researchers’ finances
Boston Globe, United States - Oct 6, 2006
… of NIH rules at the time. Selected quotation, anyone? Those rules
are now even stronger than they were before December 2003, when
David Willman exposed rampant …
Drug Companies’ Consulting Fees at Issue
Los Angeles Times, CA - Oct 6, 2006
By David Willman, Times Staff Writer. … NIH ethics rules, tightened
last year, prohibit employees from accepting any form of
pharmaceutical company stock and most …
Panel Challenges NIH Handling of Rules Violations
Los Angeles Times, CA - Sep 14, 2006
By David Willman, Times Staff Writer. … of Health agreed on at least
one point Wednesday: Private financial deals between drug companies
and NIH scientists that …
House subcomittee hearing focuses on disciplinary measures for NIH …
News-Medical.net, Australia - Sep 18, 2006
… He added that NIH currently is “clarifying its policies regarding the
presentation of scientific information” to FDA advisory committees
(Willman, Los Angeles …
There is no editorial comment or other information provided here other
than the pieces of information displayed above. We believe they speak
for themselves but if any clarification is required, please leave a comment
and we’ll get back to ya.
Stanford Matthews
MoreWhat.com staff